The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
GlobalData on MSN4d
FDA breakthrough status for Bluejay’s CHD therapy brelovitugThe US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human ...
Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...
Brelovitug has previously received Orphan and PRIME designation from the European Medicines Agency.
A revolutionary advancement in cancer treatment at UH Seidman Cancer Center is dramatically reducing the time patients spend ...
News Medical on MSN1d
Breakthrough gene discovery offers new hope for medulloblastoma therapyScientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.
Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products ...
Madison Keys attributed her breakthrough victory in securing her first Grand Slam title to extensive therapy, which she said ...
What You Need to Know The global hydrogen water market is projected to grow from USD 2.5 billion in 2024 to USD 4.35 billion ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback